Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Knowledge of and opinions on HIV preexposure prophylaxis among front-line service providers at Canadian AIDS service organizations.

Senn H, Wilton J, Sharma M, Fowler S, Tan DH.

AIDS Res Hum Retroviruses. 2013 Sep;29(9):1183-9. doi: 10.1089/AID.2013.0090. Epub 2013 Jun 22.

2.

Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.

Myers GM, Mayer KH.

AIDS Patient Care STDS. 2011 Feb;25(2):63-71. doi: 10.1089/apc.2010.0222. Review.

PMID:
21284497
3.

Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study).

King HL, Keller SB, Giancola MA, Rodriguez DA, Chau JJ, Young JA, Little SJ, Smith DM.

AIDS Behav. 2014 Sep;18(9):1722-5. doi: 10.1007/s10461-014-0845-5.

4.

Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.

Kibengo FM, Ruzagira E, Katende D, Bwanika AN, Bahemuka U, Haberer JE, Bangsberg DR, Barin B, Rooney JF, Mark D, Chetty P, Fast P, Kamali A, Priddy FH.

PLoS One. 2013 Sep 26;8(9):e74314. doi: 10.1371/journal.pone.0074314. eCollection 2013.

5.

Oral antiretroviral chemoprophylaxis: current status.

Baeten J, Celum C.

Curr Opin HIV AIDS. 2012 Nov;7(6):514-9. doi: 10.1097/COH.0b013e3283582d30. Review.

6.

Preexposure prophylaxis for HIV prevention: where have we been and where are we going?

Baeten JM, Haberer JE, Liu AY, Sista N.

J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S122-9. doi: 10.1097/QAI.0b013e3182986f69. Review.

7.

Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial.

Murnane PM, Celum C, Mugo N, Campbell JD, Donnell D, Bukusi E, Mujugira A, Tappero J, Kahle EM, Thomas KK, Baeten JM; Partners PrEP Study Team.

AIDS. 2013 Aug 24;27(13):2155-60. doi: 10.1097/QAD.0b013e3283629037.

8.

HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.

Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, Seage GR 3rd, Sloan CE, Sax PE, Walensky RP.

Clin Infect Dis. 2009 Mar 15;48(6):806-15. doi: 10.1086/597095.

9.
10.

High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project.

Cohen SE, Vittinghoff E, Bacon O, Doblecki-Lewis S, Postle BS, Feaster DJ, Matheson T, Trainor N, Blue RW, Estrada Y, Coleman ME, Elion R, Castro JG, Chege W, Philip SS, Buchbinder S, Kolber MA, Liu AY.

J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):439-48. doi: 10.1097/QAI.0000000000000479.

11.

Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.

Donnell D, Hughes JP, Wang L, Chen YQ, Fleming TR.

J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S130-4. doi: 10.1097/QAI.0b013e3182986fac.

12.

[Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine].

Boot J, Rump BO, Boucher CA, Op de Coul EL, van Agtmael MA, van de Vijver DA, Burger DM, Fanoy EB.

Ned Tijdschr Geneeskd. 2013;157(27):A6063. Review. Dutch.

PMID:
23838402
13.

Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants.

Fuchs JD, Sobieszczyk ME, Madenwald T, Grove D, Karuna ST, Andrasik M, Sherwat A, Broder G, Mayer K, Koblin B, Hammer S; HVTN 505 Protocol Team.

J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):259-62. doi: 10.1097/QAI.0b013e318296df94.

14.

[Pre-exposure prophylaxis for HIV transmission? No, unless].

Boeke AJ, Heijnen AM.

Ned Tijdschr Geneeskd. 2013;157(27):A6359. Dutch.

PMID:
23838404
15.

A perspective on progress and gaps in HIV prevention science.

Kiser PF, Mesquita PM, Herold BC.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1373-8. doi: 10.1089/AID.2012.0277.

16.
17.

Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.

de Lastours V, Fonsart J, Burlacu R, Gourmel B, Molina JM.

Antimicrob Agents Chemother. 2011 Oct;55(10):4905-7. doi: 10.1128/AAC.00120-11. Epub 2011 Jul 25.

18.

Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men.

Marcus JL, Glidden DV, McMahan V, Lama JR, Mayer KH, Liu AY, Montoya-Herrera O, Casapia M, Hoagland B, Grant RM.

PLoS One. 2014 Mar 17;9(3):e91513. doi: 10.1371/journal.pone.0091513. eCollection 2014.

19.

Ethics and pre-exposure prophylaxis for HIV infection.

Sugarman J, Mayer KH.

J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S135-9. doi: 10.1097/QAI.0b013e3182987787.

20.

Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.

Li J, Dufrene SL, Okulicz JF.

Ann Pharmacother. 2014 Apr;48(4):507-18. doi: 10.1177/1060028014520880. Epub 2014 Jan 28. Review.

PMID:
24473492

Supplemental Content

Support Center